NOVACYT (ALNOV.PA) Fundamental Analysis & Valuation

EPA:ALNOV • FR0010397232

Current stock price

0.3875 EUR
+0 (+0.91%)
Last:

This ALNOV.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ALNOV.PA Profitability Analysis

1.1 Basic Checks

  • ALNOV had negative earnings in the past year.
  • In the past year ALNOV has reported a negative cash flow from operations.
  • In the past 5 years ALNOV reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: ALNOV reported negative operating cash flow in multiple years.
ALNOV.PA Yearly Net Income VS EBIT VS OCF VS FCFALNOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

  • ALNOV has a worse Return On Assets (-48.32%) than 61.25% of its industry peers.
  • With a Return On Equity value of -74.44%, ALNOV perfoms like the industry average, outperforming 55.00% of the companies in the same industry.
Industry RankSector Rank
ROA -48.32%
ROE -74.44%
ROIC N/A
ROA(3y)-32.84%
ROA(5y)-9.46%
ROE(3y)-47.33%
ROE(5y)-12.19%
ROIC(3y)N/A
ROIC(5y)N/A
ALNOV.PA Yearly ROA, ROE, ROICALNOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

  • With a Gross Margin value of 63.35%, ALNOV perfoms like the industry average, outperforming 56.25% of the companies in the same industry.
  • ALNOV's Gross Margin has improved in the last couple of years.
  • ALNOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y75.01%
GM growth 5Y20.62%
ALNOV.PA Yearly Profit, Operating, Gross MarginsALNOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ALNOV.PA Health Analysis

2.1 Basic Checks

  • ALNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ALNOV has about the same amount of shares outstanding.
  • Compared to 5 years ago, ALNOV has more shares outstanding
  • ALNOV has a worse debt/assets ratio than last year.
ALNOV.PA Yearly Shares OutstandingALNOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ALNOV.PA Yearly Total Debt VS Total AssetsALNOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • ALNOV has an Altman-Z score of 0.43. This is a bad value and indicates that ALNOV is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.43, ALNOV is in line with its industry, outperforming 56.25% of the companies in the same industry.
  • ALNOV has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.24, ALNOV is doing good in the industry, outperforming 62.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Altman-Z 0.43
ROIC/WACCN/A
WACC6.71%
ALNOV.PA Yearly LT Debt VS Equity VS FCFALNOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • ALNOV has a Current Ratio of 5.03. This indicates that ALNOV is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 5.03, ALNOV belongs to the top of the industry, outperforming 83.75% of the companies in the same industry.
  • ALNOV has a Quick Ratio of 4.59. This indicates that ALNOV is financially healthy and has no problem in meeting its short term obligations.
  • ALNOV has a better Quick ratio (4.59) than 83.75% of its industry peers.
Industry RankSector Rank
Current Ratio 5.03
Quick Ratio 4.59
ALNOV.PA Yearly Current Assets VS Current LiabilitesALNOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ALNOV.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 17.85% over the past year.
  • ALNOV shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.50%.
  • The Revenue has been growing by 11.35% on average over the past years. This is quite good.
EPS 1Y (TTM)17.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.73%
Revenue 1Y (TTM)8.5%
Revenue growth 3Y-40.37%
Revenue growth 5Y11.35%
Sales Q2Q%-5.12%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALNOV.PA Yearly Revenue VS EstimatesALNOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ALNOV.PA Yearly EPS VS EstimatesALNOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 0 0.5 -0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

0

4. ALNOV.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALNOV. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALNOV.PA Price Earnings VS Forward Price EarningsALNOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALNOV.PA Per share dataALNOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALNOV.PA Dividend Analysis

5.1 Amount

  • No dividends for ALNOV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALNOV.PA Fundamentals: All Metrics, Ratios and Statistics

NOVACYT

EPA:ALNOV (3/16/2026, 7:00:00 PM)

0.3875

+0 (+0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-21
Earnings (Next)N/A
Inst Owners0.05%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap27.37M
Revenue(TTM)19.10M
Net Income(TTM)-30.40M
Analysts37.14
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.24
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB 1.09
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.31
BVpS0.67
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.32%
ROE -74.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.35%
FCFM N/A
ROA(3y)-32.84%
ROA(5y)-9.46%
ROE(3y)-47.33%
ROE(5y)-12.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y75.01%
GM growth 5Y20.62%
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 8.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.03
Quick Ratio 4.59
Altman-Z 0.43
F-Score4
WACC6.71%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.93%
Cap/Sales(5y)4.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.73%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.5%
Revenue growth 3Y-40.37%
Revenue growth 5Y11.35%
Sales Q2Q%-5.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.03%
OCF growth 3YN/A
OCF growth 5YN/A

NOVACYT / ALNOV.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NOVACYT (ALNOV.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALNOV.PA.


Can you provide the valuation status for NOVACYT?

ChartMill assigns a valuation rating of 0 / 10 to NOVACYT (ALNOV.PA). This can be considered as Overvalued.


Can you provide the profitability details for NOVACYT?

NOVACYT (ALNOV.PA) has a profitability rating of 1 / 10.


What is the financial health of NOVACYT (ALNOV.PA) stock?

The financial health rating of NOVACYT (ALNOV.PA) is 5 / 10.